BeeWell

Trials & centers

Ask your doctor

Pick a condition

Recruiting trials

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Phase 1 Recruiting

  • Moffitt Cancer Center, Tampa, Florida, United States
Official record

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 & 2 Recruiting

  • Research Site, Irvine, California, United States
  • Research Site, Jacksonville, Florida, United States
  • Research Site, Rochester, Minnesota, United States
  • More sites
Official record

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

Phase 2 Recruiting

  • University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Official record

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

Phase 1 Recruiting

  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering at Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
  • Memorial Sloan Kettering at Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
  • More sites
Official record

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Phase 1 & 2 Recruiting

  • Research Site, Birmingham, Alabama, United States
  • Research Site, Duarte, California, United States
  • Research Site, Los Angeles, California, United States
  • More sites
Official record

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Phase 1 Recruiting

  • Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, United States
  • University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • University of Cincinnati, Cincinnati, Ohio, United States
  • More sites
Official record

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Phase 1 & 2 Recruiting

  • St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
  • Mayo Clinic, Phoenix, Arizona, United States
  • City of Hope, Duarte, California, United States
  • More sites
Official record

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

  • Mayo Clinic Arizona, Scottsdale, Arizona, United States
  • City of Hope Medical Foundation, Duarte, California, United States
  • University of Southern California, Los Angeles, California, United States
  • More sites
Official record
ClinicalTrials.gov

NCI-designated centers

Comprehensive & clinical

Alabama

Arizona

California

Colorado

Connecticut

District of Columbia

  • Georgetown Lombardi Comprehensive Cancer Center

    Washington, District of Columbia

Florida

Georgia

Hawai'i

Illinois

Indiana

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana

Iowa

Kansas

Kentucky

Maryland

  • Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

Massachusetts

Michigan

Minnesota

Missouri

Nebraska

New Hampshire

New Jersey

New Mexico

  • University of New Mexico Cancer Research and Treatment Center

    Albuquerque, New Mexico

New York

North Carolina

Ohio

Oklahoma

Oregon

Pennsylvania

South Carolina

Tennessee

Texas

Utah

Virginia

Washington

  • Fred Hutchinson/University of Washington/Seattle Children's Cancer Consortium

    Seattle, Washington

Wisconsin

NCI-Designated Cancer Centers, June 10, 2026